Aurinia Pharmaceuticals offers a rare combination of a four-quarter earnings beat streak, elite operating margins, and a below-market forward multiple, but the stock has nearly closed the gap to its near-term resistance target and free cash flow converts at less than half of reported net income — arguing for patience over immediate deployment.
Thesis pillars
- Elite Profitability Franchise→Stable
- Consistent Earnings Outperformance→Stable
- Attractive Growth Adjusted Valuation→Stable
- +2 more pillars — see the Why tab for full reasoning
Aurinia Pharmaceuticals Inc (AUPH) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait for pullback to $15.01. Weak momentum — blocks BUY_NOW at $15.55. Engine's entry $15.01 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 1.9x (earnings normalizing); Analyst target reached - limited upside remaining.
Aurinia Pharmaceuticals markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult lupus nephritis, generating $271.3 million in 2025 net product sales. Revenue comes from direct U.S. commercialization through specialty pharmacies and a supply and royalty... Read more
Wait for pullback to $15.01. Weak momentum — blocks BUY_NOW at $15.55. Engine's entry $15.01 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 1.9x (earnings normalizing); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Fundamentals strong but target reached (-5.3% upside). Wait for pullback. Score 7.0/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About Aurinia Pharmaceuticals Inc
About Aurinia Pharmaceuticals Inc
LUPKYNIS (voclosporin), the only FDA-approved oral therapy for adult lupus nephritis, generated $271.3 million in net product sales for Aurinia Pharmaceuticals in 2025 — a 25% increase from $216.2 million in 2024 — with operating cash flows of $135.7 million, up 206% year over year. Aurinia commercializes LUPKYNIS directly in the United States and supplies product to Otsuka Pharmaceutical Co., Ltd. for Japan, the European Union, the United Kingdom, and Switzerland under a collaboration agreement signed in December 2020. The company held $398.0 million in cash, equivalents, and investments at December 31, 2025, and repurchased 12.2 million shares for $98.2 million during the year.
Aurinia sells LUPKYNIS in the U.S. through two specialty pharmacies and a specialty distributor, with payer coverage from commercial plans and government programs including Medicaid and Medicare. Outside the U.S., Otsuka has obtained regulatory approval in Japan, the EU, the UK, and Switzerland; Aurinia earns royalties of 10% to 20% on Otsuka Territory net sales. Manufacturing is entirely outsourced: Lonza is the sole supplier of voclosporin drug substance at a dedicated Monoplant facility, Catalent Pharma Solutions is the sole supplier of voclosporin capsules, and a sole supplier handles blistering and packaging of U.S. commercial cartons. In the U.S., LUPKYNIS competes against BENLYSTA (belimumab, marketed by GSK plc) and GAZYVA (obinutuzumab, marketed by Genentech, Inc.), both injectable therapies, as well as off-label use of mycophenolate mofetil and corticosteroids. In February and March 2025, eight generic companies including Hikma, Teva Pharmaceuticals, Dr. Reddy's Laboratories, and Sandoz filed ANDAs challenging the 2037 dosing patents; Aurinia filed patent infringement complaints against each, triggering a Hatch-Waxman 30-month regulatory stay.
Show full overview
Three sole-source supply relationships expose Aurinia to manufacturing disruption risk with no short-term mitigation path. Lonza serves as the sole drug substance manufacturer at a dedicated Monoplant contracted through March 31, 2030, at a fixed quarterly facility fee of 3.6 million Swiss Francs for exclusive use rights — a cost that continues regardless of production volume. Catalent Pharma Solutions is the sole encapsulator and an unnamed third supplier handles all blistering and packaging of U.S. commercial cartons. The 10-K notes that the long-term commercial success of LUPKYNIS depends in part on the ability of contract manufacturers to supply cGMP-compliant product without interruption, and that an interruption from any sole-source supplier could adversely affect LUPKYNIS commercial sales.
See also: Healthcare · Biotechnology
From Aurinia Pharmaceuticals Inc's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-05Recent Developments — Aurinia Pharmaceuticals Inc
Latest news
- NEWS Aurinia earnings on deck: Can new leadership sustain growth? By Investing.com - Investing.com Australia — Investing.com Australia neutral
- NEWS Insiders, Activists Ignite Aurinia’s Surprising Stock Surge - TipRanks — TipRanks positive
- NEWS Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences - citybiz — citybiz positive
- NEWS Aurinia Pharmaceuticals Inc (AUPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey — TradingKey neutral
- NEWS Aurinia Pharmaceuticals Inc (AUPH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - Tradin — TradingKey neutral
Generated 2026-07-05T22:40:28Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·2 ceiling hits
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $15.01. Weak momentum — blocks BUY_NOW at $15.55. Engine's entry $15.01 (Default 5pct Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 1.9x (earnings normalizing); Analyst target reached - limited upside remaining. Chart setup: No clear chart pattern; technical signals are mixed. Fundamentals strong but target reached (-5.3% upside). Wait for pullback. Target $18.86 (+21.3%), stop $13.18 (−18.0%), A.R:R -0.5:1. Score 7.0/10, moderate confidence.
Take-profit target: $18.86 (+27.2% upside). Target $18.86 (+21.3%), stop $13.18 (−18.0%), A.R:R -0.5:1. Stop-loss: $13.18.
Cyclical risk: PE expanding 1.9x (earnings normalizing); Analyst target reached - limited upside remaining; Negative momentum.
Aurinia Pharmaceuticals Inc trades at a P/E of 7.2 (forward 14.0). TrendMatrix value score: 7.2/10. Verdict: Buy (Wait for Entry).
13 analysts cover AUPH with a consensus score of 3.9/5. Average price target: $17.
What does Aurinia Pharmaceuticals Inc do?Aurinia Pharmaceuticals markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult lupus nephritis,...
Aurinia Pharmaceuticals markets LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult lupus nephritis, generating $271.3 million in 2025 net product sales. Revenue comes from direct U.S. commercialization through specialty pharmacies and a supply and royalty arrangement with Otsuka Pharmaceutical for Japan, EU, UK, and Switzerland markets. Manufacturing relies entirely on sole-source contractors: Lonza for drug substance and Catalent for encapsulation.